Founded in 2018, Huaguan Biotech focuses on core technology platforms including continuous flow plus enzymatic biosynthesis for green and safe production of active pharmaceutical ingredients, and a proprietary "one-arrow-multi-star" ADC platform targeting Linker+Payload upgrades for next-generation antibody–drug conjugates. The company operates four R&D centers in Beijing, Nanjing, Suzhou and Chongqing. It is constructing a 100-mu green API GMP production base in Fuyang, Anhui. Huaguan supplies R&D services and products to numerous leading enterprise clients and has attracted equity investments from several listed-company industrial funds. Its technology and service positioning emphasize sustainable, scalable API manufacturing and advanced ADC development. Recently the company completed a B round financing of over RMB 100 million, reflecting external investor support for its growth plans.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2022